Notice Number: NOT-AR-18-007
Release Date: April 13, 2017
Estimated Publication Date of Announcement: June 2017
First Estimated Application Due Date: November 2017
Earliest Estimated Award Date: June 2018
Earliest Estimated Start Date: July 2018
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
This Notice serves to alert the research community that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) intends to reissue PAR-14-192, 'Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R21),' to encourage applications for short-term clinical trials.
The goal of the NIAMS clinical trial program is to prevent or reduce symptoms and improve outcomes and function in patients with rheumatic, musculoskeletal or skin diseases. The purpose of the Exploratory Clinical Trials Grants Program is to foster short-term interventional studies in humans that will ultimately lead to clinically meaningful improvements in prevention, diagnosis, or treatment of these diseases.
The NIAMS has updated the requirements for clinical trials that are allowable through the R21 mechanism, which may impact applications submitted in response to this FOA. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.
The FOA is expected to be published in Summer 2017 with an expected application due date in Fall 2017.
This FOA will utilize the R21 activity code.
A broad range of types of exploratory studies may be submitted in response to this FOA. The trials must address research questions related to the mission and goals of the NIAMS and may evaluate interventions with drugs, biologics, devices, or surgical, dietary, behavioral or rehabilitation therapies. The trials must be feasible within the budget and time constraints of the funding mechanism. Submission of collaborative projects, which involve both investigators with expertise in rheumatic, musculoskeletal or skin diseases and those with clinical trial experience and relevant statistical expertise, is encouraged.
APPLICATIONS ARE NOT BEING SOLICITED AT THIS TIME.
Please direct all inquiries to: